Concord Biotech Completes ANVISA Inspection at Limbasi API Facility
Concord Biotech Limited has announced the successful completion of an inspection by the Brazilian Health Regulatory Agency, ANVISA, conducted at its API manufacturing facility located in Limbasi. The inspection took place from June 8 to June 12, 2026, concluding with a successful outcome.The successful completion of the ANVISA inspection is described as a significant milestone for Concord Biotech's global expansion efforts. This achievement reinforces the company's dedication to maintaining the highest standards of quality and regulatory excellence.
This international validation strengthens the company's global manufacturing and regulatory footprint. It also advances Concord Biotech's strategy for international growth by enhancing access to one of the world's largest pharmaceutical markets, thereby broadening the reach of its high-quality APIs across key global geographies.
CONCORDBIO Stock Price Movement
As of 1:41 PM, shares of Concord Biotech Limited are edging higher to ₹1353.9, reflecting an intraday increase of 0.79% or ₹10.60. Trading activity continues strongly as 190,895 shares are currently traded in the market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.